The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients

Launched by QUEEN MARY HOSPITAL, HONG KONG · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a special test called a thrombin generation assay to see if it can help detect blood clots related to central lines (thin tubes placed in veins) in critically ill patients. Blood clots can be a serious complication for patients with central lines, which are often used for treatments like medication delivery or dialysis. The researchers want to understand how well this test works in patients who have these central lines, as well as those who do not have any blood clots.

To be part of this study, participants need to be at least 18 years old and admitted to the intensive care unit at Queen Mary Hospital in Hong Kong. They must also need a central line placed for at least five days. However, patients with certain conditions, such as existing blood clots or specific health issues, will not be included in the study. If eligible, participants can expect to undergo the thrombin generation test during their hospital stay, which can help doctors learn more about their risk of developing blood clots. This research aims to improve care for patients in critical conditions and could lead to better detection and prevention of complications from central lines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≧ 18; AND
• • Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital in Hong Kong; AND
• • Clinically indicated for central catheter insertion, which includes central venous catheters and dialysis catheters; AND
• • Expected to have the central catheter in place for at least 5 days in their ICU stay.
• Exclusion Criteria:
• • Patients known to have active venous thromboembolism including deep venous thrombosis or pulmonary embolism;
• • Patients known to have hypercoagulable states, e.g., hereditary thrombophilia, antiphospholipid syndrome; OR
• • Patients with active solid organ or hematological malignancies; OR
• • Patients already receiving therapeutic anticoagulation prior to study recruitment; OR
• • Patients with thrombosis detected in the insertion site before central catheter insertion; OR
• • Patients with a central venous catheter already in place prior to ICU admission; OR
• • Patients admitted to the ICU for post-operative care; OR
• • Patients admitted to the ICU for trauma care; OR
• • Patients requiring extra-corporeal life support (ECLS); OR
• • Patients with poor window or inaccessible for ultrasonographic examination; OR
• • Pregnancy/post-partum within 6 weeks